peginterferon alfa-2b 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
5164 215647-85-1

Description:

MoleculeDescription

Synonyms:

  • peginterferon alfa-2b
  • pegintron
A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
7.50 mcg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Jan. 19, 2001 FDA SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count decreased 489.85 34.77 181 2925 136788 90488553
Anaemia 473.49 34.77 232 2874 352570 90272771
White blood cell count decreased 249.86 34.77 119 2987 166990 90458351
Neutrophil count decreased 188.32 34.77 76 3030 71456 90553885
Blood bilirubin increased 163.79 34.77 60 3046 43410 90581931
Haemoglobin decreased 139.90 34.77 80 3026 161876 90463465
No adverse event 112.21 34.77 52 3054 67930 90557411
Product quality issue 89.99 34.77 47 3059 79278 90546063
Pyrexia 89.40 34.77 111 2995 660374 89964967
Hepatitis C 54.84 34.77 16 3090 5644 90619697
Hepatocellular carcinoma 47.76 34.77 12 3094 2416 90622925
Decreased appetite 45.47 34.77 60 3046 376480 90248861
Exposure via father 45.33 34.77 8 3098 290 90625051
Malaise 40.45 34.77 72 3034 585914 90039427

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count decreased 304.11 29.30 170 3343 138411 42479411
Anaemia 293.09 29.30 215 3298 280063 42337759
White blood cell count decreased 200.39 29.30 120 3393 110276 42507546
Product quality issue 164.35 29.30 60 3453 17822 42600000
Hepatocellular carcinoma 136.54 29.30 43 3470 8151 42609671
Neutrophil count decreased 109.68 29.30 67 3446 63348 42554474
Blood bilirubin increased 103.42 29.30 56 3457 42196 42575626
Haemoglobin decreased 86.93 29.30 78 3435 132393 42485429
Pyrexia 82.75 29.30 129 3384 393913 42223909
No adverse event 66.78 29.30 41 3472 38980 42578842
Influenza like illness 66.37 29.30 38 3475 31802 42586020
Hyperbilirubinaemia 46.69 29.30 26 3487 20609 42597213
Rash 35.05 29.30 73 3440 276881 42340941
Insomnia 32.23 29.30 44 3469 118209 42499613
Treatment failure 29.83 29.30 31 3482 62593 42555229

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count decreased 814.10 29.02 346 5845 230097 110353011
Anaemia 744.47 29.02 428 5763 546658 110036450
White blood cell count decreased 462.06 29.02 234 5957 229156 110353952
Neutrophil count decreased 304.55 29.02 144 6047 120797 110462311
Blood bilirubin increased 272.76 29.02 116 6075 75856 110507252
Haemoglobin decreased 238.95 29.02 157 6034 248570 110334538
Hepatocellular carcinoma 180.49 29.02 51 6140 9829 110573279
Pyrexia 177.29 29.02 233 5958 898032 109685076
Hyperbilirubinaemia 78.42 29.02 37 6154 30634 110552474
Influenza like illness 70.75 29.02 50 6141 88362 110494746
Product quality issue 67.20 29.02 46 6145 77253 110505855
Decreased appetite 59.36 29.02 100 6091 475746 110107362
Pruritus 52.12 29.02 106 6085 581454 110001654
Leukopenia 51.72 29.02 52 6139 148739 110434369
Hyperuricaemia 51.39 29.02 22 6169 14509 110568599
Rash 48.58 29.02 127 6064 820837 109762271
Hepatitis C 47.67 29.02 20 6171 12553 110570555
Malaise 46.09 29.02 110 6081 671709 109911399
Neutropenia 44.38 29.02 77 6114 374543 110208565
Insomnia 42.55 29.02 74 6117 360516 110222592
Retinopathy 38.74 29.02 13 6178 4416 110578692
Hepatic cirrhosis 35.94 29.02 30 6161 67596 110515512
Haemolytic anaemia 35.14 29.02 19 6172 20901 110562207
Liver transplant 30.59 29.02 11 6180 4578 110578530
Red blood cell count decreased 30.47 29.02 27 6164 65896 110517212

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L03AB10 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Interferons
ATC L03AB60 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Interferons
FDA CS M0025711 Interferon-alpha
FDA EPC N0000175521 Interferon alpha
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000182138 Cytochrome P450 1A2 Inhibitors
FDA EPC N0000193883 Antiviral

Related Drugs by ATC class:

L03AB Interferons 6 drugs
interferon alfa-2binterferon beta-1ainterferon beta-1bpeginterferon alfa-2apeginterferon beta-1aropeginterferon alfa-2b

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic hepatitis C indication 128302006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interferon alpha/beta receptor Membrane receptor AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
G8RGG88B68 UNII
4021256 VANDF
C0796545 UMLSCUI
CHEMBL1201561 ChEMBL_ID
DB00022 DRUGBANK_ID
7909 INN_ID
C417083 MESH_SUPPLEMENTAL_RECORD_UI
7462 IUPHAR_LIGAND_ID
253453 RXNORM
129477009 SNOMEDCT_US
395823000 SNOMEDCT_US
15887 MMSL
41030 MMSL
d04746 MMSL
008329 NDDF

Pharmaceutical products:

None